Veracyte SOAR Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This Veracyte SOAR Analysis gives you a clear, structured view of the company's strengths, opportunities, aspirations, and results for research, strategy, or investing. The page already includes a real preview of the actual deliverable, so you can review the content before buying. Purchase the full version to get the complete ready-to-use analysis.
Strengths
Deep genomic database fueling a strategic clinical flywheel
Veracyte's Decipher GRID gives it a deep data moat: management says the library topped 100,000 whole-transcriptome profiles by 2026, with the base already expanding through 2025. That scale lets Veracyte iterate, validate, and tune new tests faster than single-marker rivals, while improving risk models with each added case. In precision oncology, more transcriptomic data means better prediction, and better prediction strengthens the clinical flywheel.
Dominant market share in urological oncology diagnostics
Veracyte's Decipher Prostate holds more than 60% of the US localized prostate cancer market, giving the Company a clear lead in urologic oncology diagnostics. In fiscal 2025, this single asset generated over $310 million in revenue, showing how Veracyte turned clinical utility into strong commercial scale. That share and revenue base raise the bar for rivals trying to win adoption in academic and community urology centers.
Sustained operational excellence and EBITDA expansion
Veracyte delivered sustained operating strength in 2025, lifting adjusted EBITDA margin to 27.6%, a full year ahead of its 25% target. That level of profitability shows a business that can fund heavy R&D while still generating cash. With more than $200 million in cash and a clean balance sheet, Veracyte can pursue internal growth or acquisitions without needing equity dilution.
Leading clinical evidence through peer-reviewed validation
Veracyte's Diagnostics Platform had more than 15 studies at the 2026 American Urological Association meeting, a strong sign of peer-reviewed clinical backing. That steady stream of real-world data helps keep the tests in National Comprehensive Cancer Network guidelines and supports reimbursement from major payers.
For physicians, repeated validation lowers adoption risk and reinforces clinical trust across thousands of urology specialists.
Anchored presence in thyroid diagnostic testing
Veracyte's Afirma platform remains a core strength in thyroid diagnostics, with nearly 68,000 patients tested in 2025. Afirma testing revenue rose 9% to about $173 million in the last fiscal year, showing steady demand and dependable cash flow. That scale also gives Veracyte an established sales base it can use to support newer diagnostic launches in other disease areas.
Veracyte's 2025: Two Growth Engines, Strong Profits
Veracyte's strengths in fiscal 2025 came from scale and proof: Decipher Prostate generated over $310 million, while Afirma testing revenue was about $173 million. That revenue mix shows two durable franchises, not one-off wins.
The Company also kept building its data moat, with Decipher GRID exceeding 100,000 whole-transcriptome profiles by 2026 after steady 2025 growth. More data means stronger models, faster test refinement, and harder-to-copy clinical insight.
Profitability was another clear strength: adjusted EBITDA margin reached 27.6% in fiscal 2025, ahead of the 25% target, with more than $200 million in cash supporting growth.
| Metric | Fiscal 2025 |
|---|---|
| Decipher Prostate revenue | >$310 million |
| Afirma testing revenue | ~$173 million |
| Adjusted EBITDA margin | 27.6% |
| Cash | >$200 million |
What is included in the product
Detailed Word Document
Editable Excel File
Opportunities
Expansion into the minimal residual disease monitoring market
Veracyte's first TrueMRD test for muscle-invasive bladder cancer is slated for the first half of 2026, and that shifts the model from a one-time diagnostic to repeated monitoring. Bladder cancer care is a recurring-use market: the U.S. sees about 83,000 new bladder cancer cases a year, and recurrence risk makes serial testing clinically relevant. Even a small share of this follow-up market could turn into steadier, higher-margin revenue starting in late 2025.
US market entry for Prosigna as an LDT
Veracyte's plan to launch Prosigna as a US laboratory developed test by mid-2026 could speed results and fit cleaner into hospital workflows, while using its South San Francisco lab base. The opportunity is large: the American Cancer Society projects about 317,000 new invasive breast cancer cases in the US in 2025. Because Prosigna is already an international IVD kit, the LDT path can deepen US reach faster.
Geographic growth through a decentralized global kit model
Veracyte's international revenue now makes up about 20% of total income, and its decentralized kit model lets local labs run tests on site. That shift away from shipping every sample to the U.S. cuts logistics costs and shortens turnaround times, which matters in 2025-2026. It also opens more room in Europe and Asia, where sample export rules can be strict.
Next-generation AI integration for prognostic insights
Veracyte's push to add AI and deep bioinformatics to Decipher can lift the product from risk scoring to therapy prediction, which is more valuable in prostate cancer care. Predictive signatures that flag likely docetaxel benefit in PTEN-inactive metastatic disease can support companion diagnostics deals with large biopharma partners. That raises the chance of higher-margin, repeatable revenue versus single-test use.
Lung cancer diagnostics scaling from screening pipelines
Completion of enrollment in the NIGHTINGALE study can let Veracyte finish its pre-malignant lung cancer screening offer and test a large new market. In the U.S., about 76 million adults are current or former smokers, so even modest uptake could scale fast if data supports use in screening pathways. A non-invasive nasal swab or biopsy-based test would also reduce Veracyte's dependence on urology revenue and broaden its diagnostics mix.
Veracyte's 2025-2026 Growth Catalyst: Repeat Testing and Global Scale
Veracyte's biggest 2025-2026 opportunity is turning one-time tests into repeat monitoring, led by TrueMRD in muscle-invasive bladder cancer and a U.S. Prosigna LDT launch. That widens access in large cancer markets, including about 83,000 U.S. bladder cases and 317,000 invasive breast cases projected for 2025. Its 20% international revenue base and AI upgrades to Decipher also support faster global scale and higher-value deals.
| Opportunity | 2025-2026 signal |
|---|---|
| TrueMRD | Repeat testing in bladder cancer |
| Prosigna | U.S. LDT launch by mid-2026 |
| Global reach | 20% revenue from outside U.S. |
Full Version Awaits
Veracyte Reference Sources
This preview shows the actual Veracyte SOAR Analysis document you'll receive after purchase – same structure, same content, no placeholders. Once you complete checkout, the full report is unlocked for immediate use. What you see here is a direct preview of the final file.
Aspirations
Becoming the universal global leader in genomic diagnostics
Veracyte is aiming to turn its diagnostics platform into the clinical guide for five high-prevalence cancers: thyroid, lung, prostate, bladder, and breast. Management's 2027 goal is clear: move from a niche specialist to a broader global diagnostics leader with guideline-backed tests across major oncology pathways.
That matters because genomic testing is becoming standard care, and a platform with broad clinical use can scale faster than a single-disease franchise.
Transforming patient outcomes through one million unique tests
Veracyte said CEO Marc Stapley is targeting the company's one millionth cumulative patient by end-2026, building on 2025 testing volume and a growing menu in lung, thyroid, and bladder cancer. That scale would help make Veracyte a default choice for complex diagnostic decisions, where clinicians want fast, evidence-backed answers. Hitting the milestone would also deepen brand trust and make the company harder to replace in standard-of-care workflows.
Scaling to more than 600 million dollars in annual revenue
Veracyte's 2026-2027 goal of passing $600 million in annual revenue is ambitious but clear: it depends on 14% to 16% yearly test-volume growth from both core business demand and new test adoption. That pace would require roughly 1.14x to 1.16x annual expansion, which is strong for a clinical lab and genomics player. If Veracyte reaches that scale, it should move into the mid-cap leadership tier and gain more weight with payers, providers, and investors.
Leading the shift to biologically informed treatment strategies
Veracyte is trying to move from classifying tumors to guiding response-adapted care across most urology and respiratory tests. By pairing TrueMRD and whole-genome sequencing, it wants to tell clinicians not just what a cancer is, but which drugs it is likely to respond to, pushing Veracyte closer to the oncology-biotech space than traditional pathology.
Sustaining long-term industry-leading profitability metrics
Veracyte's 2026-and-beyond goal is to keep adjusted EBITDA margins at or above 25%, showing that a high-growth genomic Company can grow without burning cash. That matters because steady margins create internal capital for future product launches and lower the need to raise outside funds. In 2025, the key test is whether the Company can keep that profit level while funding growth.
Veracyte Targets $600M+ Revenue and 1M Patients by 2026
Veracyte's aspiration is to become the go-to genomic diagnostics platform across thyroid, lung, prostate, bladder, and breast cancer, with 2026-2027 goals tied to guideline-backed adoption, 1 million cumulative patients by end-2026, and more than $600 million in annual revenue. The Company is also targeting 14% to 16% yearly test-volume growth and 25%+ adjusted EBITDA margins, showing it wants scale without losing profit discipline.
| 2025 focus | Target |
|---|---|
| Patient milestone | 1 million by end-2026 |
| Revenue | $600M+ annualized |
| Volume growth | 14% to 16% |
| Adjusted EBITDA margin | 25%+ |
Results
Exceptional 2025 revenue performance beating historical guidance
Veracyte posted 2025 revenue of $517.1 million, up 16% year over year and above prior guidance. Record Decipher and Afirma volumes drove the beat, with both products topping Wall Street estimates in the second half of 2025. Management now expects 2026 revenue of $570 million to $582 million, signaling continued momentum.
Total annual testing volumes reaching record levels
Veracyte's total patient tests rose 19% in 2025 to 179,528, a record driven by deeper reach into community physician networks. Decipher was the main growth engine, up 27% to about 102,000 tests and now the largest volume contributor. That mix shows the clinical sales force is converting broader access into steady test adoption across the portfolio.
Significant cash-flow generation and balance sheet strength
Veracyte generated $136.3 million of net cash from operating activities in 2025, more than double the $61 million in 2024, showing the commercial lab model is now producing strong cash. With about $215 million in liquidity, the Company has room to fund the planned 2026 launches of Prosigna and TrueMR without near-term balance sheet stress.
Early achievement of margin targets through efficiency
Veracyte's 2025 European restructuring paid off early, lifting adjusted EBITDA margin to 27.6% for the full year, above the 25% long-term target and one year ahead of plan. Revenue growth is now clearly outrunning admin and lab cost growth, showing real operating leverage. That gap matters: it means more of each new dollar of revenue is flowing to profit.
Broad insurance coverage protecting test accessibility
Veracyte's core tests now have payer coverage across 280 million total lives in private and public plans, which cuts access friction for patients and helps protect lab collections. The company's average selling prices have stayed near $2,900, showing that broad coverage supports pricing power and lowers bad-debt risk. In US diagnostics, near-universal coverage for key tests is a strong moat that newer startups usually cannot match.
Veracyte Delivers Strong 2025 Growth and Cash Flow
Veracyte's 2025 results were strong: revenue rose 16% to $517.1 million and total patient tests increased 19% to 179,528. Decipher led growth, up 27% to about 102,000 tests, while adjusted EBITDA margin reached 27.6%.
Cash generation also improved sharply, with operating cash flow rising to $136.3 million in 2025 from $61 million in 2024. The Company ended with about $215 million in liquidity.
| 2025 | Value |
|---|---|
| Revenue | $517.1M |
| Tests | 179,528 |
| Op. cash flow | $136.3M |
Frequently Asked Questions
Veracyte leads via a massive genomic data moat and commercial dominance in urology. Its Decipher GRID contains over 100,000 transcriptome profiles, allowing for faster research cycles than peers. Additionally, the company captured more than 60 percent market share in localized prostate cancer, generating $310.7 million in Decipher revenue for 2025. This scale enables consistent adjusted EBITDA margins of roughly 27 percent.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.